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AbstrAct:
Recent developments in multi-functional nanoparticles offer a great potential for 
targeted delivery of therapeutic compounds and imaging contrast agents to specific 
cell types, in turn, enhancing therapeutic effect and minimizing side effects. Despite 
the promise, site specific delivery carriers have not been translated into clinical 
reality. In this study, we have developed long circulating liposomes with the outer 
surface decorated with thioated oligonucleotide aptamer (thioaptamer) against 
E-selectin (ESTA) and evaluated the targeting efficacy and PK parameters. In 
vitro targeting studies using Human Umbilical Cord Vein Endothelial Cell (HUVEC) 
demonstrated efficient and rapid uptake of the ESTA conjugated liposomes (ESTA-
lip). In vivo, the intravenous administration of ESTA-lip resulted in their accumulation 
at the tumor vasculature of breast tumor xenografts without shortening the 
circulation half-life. The study presented here represents an exemplary use of 
thioaptamer for targeting and opens the door to testing various combinations of 
thioaptamer and nanocarriers that can be constructed to target multiple cancer 
types and tumor components for delivery of both therapeutics and imaging agents.
INtrOdUctION
Treatment for solid tumors has largely relied on 
initial surgical intervention and subsequent scheduled 
cytotoxic chemotherapies. However, the vast majority 
of malignancies have proven to be resistant to these 
approaches, partially due to the requisite dose limitations 
for preventing adverse effects on normal tissues. Recent 
advances in multi-functional drug delivery systems 
provide insight into development of nanoscale carriers for 
cancer treatment and imaging [1-3]. Current nanoscale 
delivery systems that are approved by FDA rely on passive 
targeting through leaky vessels, which is a hallmark 
of tumor vasculature [4, 5]. This class of nanoparticles 
improves the solubility, toxicity profile, and unfavorable 
pharmacokinetics of the chemotherapeutics. However, 
the therapeutic efficacy remains largely unchanged [6, 
7]. Therefore, development of a tool to allow for constant 
and selective delivery of therapeutics is desirable. Active 
targeting can be achieved by efficient recognition of 
tumor specific antigens that are differentially expressed 
cell surface proteins between normal and tumor. An 
affinity-based interaction between the antigens and 
targeted ligand increase delivery efficacy by enhancing 
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the retention of nanoparticles and elevating cellular uptake 
while minimizing side effects associated with potential 
off-targeting [1]. 
Among tumor components, tumor vasculature is 
an attractive target for the delivery of anti-cancer and 
imaging contrast agents. The concept of tumor vasculature 
targeting is substantially distinct from targeting cancer 
cells [1, 8]. When nanoparticles are administered 
intravenously to target cancer cells, they are required 
to physically cross over the layers of endothelial lining 
against oncotic pressure that is generated from inside the 
tumor microenvironment. In contrast, for vasculature 
targeted nanoparticles, the intended molecular targets 
on the endothelial cell surface are readily accessible to 
the circulating nanoparticles. Tumor vasculature is in 
an inflamed state and overexpresses several important 
factors such as adhesion molecules [9, 10]. E-selectin 
(CD62E, ELAM-1 or LECAM-2) is selectively 
expressed in inflamed vasculature in advanced tumors 
by cytokines that are secreted in the inflammatory tumor 
microenvironment [11-13]. The inducible nature of 
E-selectin in the inflammatory environment would allow 
for site specific delivery of nanoparticle to the inflamed 
tumor vasculature and possibly to tumor parenchyma 
via subsequent extravasation. We recently identified 
a thiophosphate-backbone modified oligonucleotide 
aptamer (“thio”aptamer) that binds E-selectin 
expressed on endothelial cells with high affinity and 
specificity [14]. In this study, we developed E-selectin 
thioaptamer conjugated stealth liposomes and analyzed 
physico-chemical properties, targeting efficiency, and 
pharmacokinetics. We herein report on 1) application of 
thioated aptamer for drug delivery, 2) tumor vasculature 
targeting, and 3) the effect of aptamer conjugation on 
pharmacokinetics of stealth liposomes.
rEsULts
development of EstA conjugated liposomes
We first developed ESTA conjugated liposome 
(ESTA-lip) for effective vasculature targeting. The 
efficiency of conjugation was evaluated by coupling 
Cy3 labeled carboxylated ESTA (COOH-Cy3-ESTA) on 
amino PEGylated stealth liposome (NH2-PEG-lip) (A) 
and the intensity of red fluorescence was measured at 
anexcitation/ emission of 544/594 nm using a fluorimeter. 
A linear standard curve was generated from Cy3-labeled 
ESTA. Approximately 50% of the surface amino groups 
presenton the liposome were conjugated to the ESTA 
(~485 ESTA molecules conjugated to one liposome) (Fig. 
1B). The physico-chemical properties of the liposomes 
wereanalyzed by a zeta-sizer and Fourier Transform 
InfraRed spectroscopy (FTIR). The size of NH2-PEG-
lip was 110.2nm in average, and ESTA conjugation 
caused a slight increase of size of the liposomes (119.3 
nm) (Fig. 1C). The analysis of zeta-potential showed 
that ESTA conjugation resulted in a substantial change 
of the surface charge of the NH2-PEG lip from +5.5 ± 
1.7 mV to -5.6 ± 2.8 mV (Fig. 1C). This indicated that 
the positive charge of the amino groups on the liposome 
surface was substituted by the negatively charged ESTA. 
Figure 1: Physico-chemical properties of EstA conjugated liposomes. (A) Scheme of TA conjugation to liposome. (B) Quantification 
of ESTA conjugation on the liposomes. Fluorescence intensity of Cy3-labeled ESTA was plotted against ESTA concentration. Using the 
standard curve the number of ESTA molecules on ESTA-lip was estimated based on fluorescence measurement. (C) Size and charge of the 
liposomes. The size of the liposomes was measured using a dynamic light scattering (DLS) and the surface charge was measured by zeta 
potential. (D) FTIR spectrum of the non labeled-liposomes and ESTA-lips. 
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Figure 2: E-selectin dependent binding of EstA-lip on E-selectin expressing cells. (A) Induction of E-selectin expression on 
the HUVEC cells. HUVEC were stimulated with TNF-α (10ng/ml) for 4 hours. Cells were dissociated with 5mM EDTA and then incubated 
with FITC labeled E-selectin antibody. Surface fluorescence was measured by flow cytometry and averaged for three separate experiments. 
(B) ESTA-lip binding to the HUVEC expressing E-selectin. HUVEC was incubated with TNF-α (10ng/ml) for 3 hours to induce E-selectin 
expression. The cells were further incubated with Cy3-ESTA-lip-FITC (10 nM) for 2 hours. All images were captured at the same exposure 
condition for comparison. The final images shown are representative images (at the final magnification: x600) from five random fields of at 
least three independent experiments. Blue, Hoechst 33342; Red, ESTA; Green, FITC-lip. (C) Immunohistochemical analysis for E-selectin 
expression on the vasculature of mouse bearing breast xenograft tumor derived from MDA-MB-231. ESTA-lip-Rhodamine were intravenously 
injected and the tumor was dissected 5 hr after the injection and frozen sections were generated to identify the localization of the liposomes 
by using fluorescent microscope. (D) ESTA-lip accumulation in tumor parenchyma after 48 hr after the injection. Red, lip-Rhodamine; Blue, 
Hoechst 33342. 
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Additionally, the spectra acquired from FTIR analysis of 
the Cy3-ESTA-lip were compared to the NH2 PEG lip and 
ESTA (Fig. 1D). A reduction in peaks corresponding to 
C=O stretch (1650 cm-1) and C-O stretch (1230 cm-1) as 
compared to the non-reactive peak corresponding to P=O 
bending (1040 cm-1) was observed in ESTA-lip. The O-H 
bend in the COOH-ESTA (1480 cm-1) appeared slightly 
shifted and partially reactive due to the contribution of 
O-H from water. Taken together, these data demonstrated 
the successful conjugation of COOH-Cy3-ESTA to the 
NH2-PEG-lip.
Binding of ESTA-lip to inflamed endothelial cells
To test binding efficiency of ESTA-lip in vitro, 
HUVEC were stimulated with TNF-α to induce E-selectin 
expression on the cell membrane. TNF-α treatment 
increased the expression of E-selectin more than 20-
fold when compared to untreated cells (Fig. 2A). The 
TNF-α treated cells were used to test the ability of the 
Cy3-ESTA-lip-FITC (Cy3-ESTA conjugated liposome 
containing FITC) to bind to E-selectin on the HUVEC 
cell surface. The cells treated with Cy3-ESTA-lip-FITC 
at a concentration of 10 nM showed intense FITC and 
Cy3 fluorescence in the cells stimulated with TNF-α 
when compared with un-stimulated controls (Fig. 2B).
The merged fluorescence of FITC and Cy3 suggest that 
the Cy3-ESTA-lip-FITC were internalized after binding 
to E-selectin on the cell surface. This co-migration of 
both thioaptamer and liposome was observed within 24 
hours (data not shown). Regardless of TNF stimuli, un-
conjugated liposomes as negative control only showed 
minor interaction to the cells and the fluorescent signal was 
almost undetectable after normalization (supplemental 
figure 1). To further examine selective binding of ESTA-
lip to E-selectin in vivo, ESTA-lip-Rhodamine was i.v. 
injected into mice bearing breast tumor xenografts (Figure 
2C). The expression level of E-selectin was upregulated on 
the tumor vasculature of xenograft tumors, predominantly 
expressed in or neighboring regions of tumor stroma 
(Fig. 2C, left). The mouse bearing tumors received an 
injection of ESTA-lip-Rhodamine via tail vain, and the 
mice were sacrificed 5 h post-injection to harvest the 
tumor and the major organs. Intravenous bolus injection 
of the ESTA-lip-Rhodamine (3 mg of liposome in 100 µl 
saline) resulted in an accumulation of red fluorescence 
on the tumor vasculature (Fig. 2C, right), while minimal 
level of fluorescence was detected around the vessel area 
when un-conjugated-lip was injected (data not shown). In 
contrast, ESTA conjugation did not affect accumulation 
of liposomes in the sinusoidal organs (data not shown). 
These data demonstrated that ESTA-lip preferentially 
binds to E-selectin expressing human and mouse 
endothelial cells in vitro and in vivo. Furthermore, 48 h 
after the injection, ESTA-lip accumulation in the tumor 
parenchyma was increased markedly (Fig. 2D), suggesting 
that enhanced tumor vasculature targeting may facilitate 
subsequent extravasation of the liposomes into tumor 
parenchyma. Interestingly, the appearance of speckled 
patterns obtained from these experiments was similar to 
that of ESTA alone [14]. This speckled pattern might be 
due to either intracellular vesicle localization or simply 
a reflection of clustered and discontinuous E-selectin 
expression pattern on the cell surface [15]. Several studies 
suggest that E-selectin internalizes and undergoes a 
recycling following membrane sorting. In addition, our 
3-D confocal imaging analysis of E-selectin expressing 
endothelial cells demonstrated intracellular localization of 
ESTA, suggesting internalization of ESTA (unpublished). 
Although binding kinetics were not measured, 50% of 
the coverage of the liposomes containing 1.1 % amine-
PEG with ESTA was sufficient to produce high-retention 
kinetics (Fig. 2B and C). In this study, we formulated the 
liposomes to contain 1.1% of amino-PEG, although the 
ratio can be modified up to 5% to further enhance the 
amounts of ESTA bioconjugation to increase binding 
specificity and affinity.
Pharmacokinetics of EstA-lip
Pharmacokinetics of the liposomes was then analyzed 
by taking whole blood at different time points after a 
single intravenous bolus administration of the ESTA-lip- 
Rhodamine or NH2-PEG-lip into 10 weeks old FBV mice. 
The fluorescence intensity originated from Rhodamine in 
the plasma of the treated mice over the untreated mice 
was assessed. Following a one compartmental model, 
the pharmacokinetics parameters were determined. There 
was no significant difference in the initial volume of 
distribution between two types of liposomes (4.2 ± 0.2 
Kel (hr-1)a T1/2 (hr)b Vd (mL)c AUC (mg.hr/mL)e CL (mL/hr)d
PEG-lip 0.030 ± 0.004 24 ± 4 4.2 ± 0.2 24848 ± 4897 0.12 ± 0.03
ESTA- 
lip 0.022 ± 0.004 32 ± 7 4.2 ± 0.4 33349 ± 4236 0.09 ± 0.01
a The elimination rate constant (kel) was obtained from the linear regression plot of the log Cp vs time curves. bThe half life (T1/2) was calculated 
using the formula: T(1/2)= 0.693/kel. cVolume of distribution (Vd) was calculated using the formula: Vd= dose/ Co , where Co is the extrapolated 
initial concentration. dArea under the curve was calculated from the formula: AUC= Co/Kel, eThe Clearance (CL) was calculated using the formula: 
CL= Kel x Vd
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mL for NH2-PEG-lip vs. 4.2 ± 0.4 mL for ESTA-lip). On 
the other hand, ESTA conjugation resulted in a decrease in 
the clearance rate (CL) (0.12 ± 0.03 μg.h for NH2-PEGlip 
vs. 0.09 ± 0.01 μg.h for ESTA-lip), and in turn led to an 
increase of the area under the curve (AUC) (24848 ± 4897 
µg.h/mL for NH2-PEG-lip vs. 33349± 4236 µg.h/mL for 
ESTA-lip) and slight extension of the circulation half-life 
(T
1/2
) (23 ± 4 h for the NH2-PEG-lip vs. 32 ± 7 h for ESTA-
lip). This data supported that the presence of thioaptamer 
ligands (ESTA) on the surface of stealth liposomes does 
not cause a reduction of the bioavailability. 
dIscUssION
Many targeted delivery systems have been 
developed using different types of nanoparticles and 
ligands for both imaging and drug delivery [16-20]. While 
antibodies have been the mainstay for active targeting, the 
use of antibodies or peptide based ligands for nanocarriers 
remains a challenge [21-23]. For example, it is difficult 
to control the orientation of antibody on the surface of 
nanocarriers by chemical conjugation since there are a 
number of reactive groups within a molecule, and such 
random conjugation may lead to unexpected off-target 
effects as well as poor targeting performance. More 
importantly, antibody conjugation to carriers causes 
a reduction in serum half-life due to the clearance by 
phagocytes in tissues and peripheral circulation [21-23]. 
The use of humanized or fragmented antibodies may 
address this issue; however, such strategies appear to be 
neither cost effective nor practical. For this reason, we 
selected thioaptamer. Aptamers are structurally distinct 
RNA and DNA oligonucleotides that have been shown 
to mimic protein-binding molecules, and yet exhibit high 
(nM to pM) binding affinity and selectivity [24], and 
can be an attractive alternative over antibody or peptide 
ligands based on their biological and chemical properties 
including, 1) small size, 2) high affinity binding, 3) low 
toxicity and immunogenicity, 4) simple and inexpensive 
chemical synthesis and modification process, and 5) 
ability to define the orientation during conjugation[25]. 
Among the aptamers that have been identified so far, 
two DNA classes of aptamers against prostate-specific 
membrane antigen (PSMA) [26] and nucleolin [27] have 
been conjugated to nanoparticles, for the cancer cell 
specific targeted drug delivery, and demonstrated effective 
delivery of chemotherapeutic agent specifically to cancer 
cells [28, 29].
As expected, ESTA conjugation to stealth liposome 
did not compromise the T
1/2, 
and rather caused a slight 
extension of the T
1/2
. The mechanisms underlying extended 
T
1/2
 of ESTA-lip is not clear. One possible explanation 
might be that the negative surface charge of ESTA-lip (-7.5 
± 0.9 mV) attributed from substitution of the surface amino 
groups might have reduced the interaction of ESTA-lip to 
the negatively charged immune cell surfaces. Nevertheless, 
our finding points to the direction that thioaptamer 
conjugation is not likely to cause a loss of stealth effect 
of nanoparticles. Active targeting of stealth liposome may 
allow for a reduction in the dose of administration and/or 
decrease toxicity for the chemotherapeutics. In this study, 
we focused on E-selectin targeted thioaptamer (ESTA) 
and stealth liposomes, however, the combinations of type 
of aptamer and nanoparticles are virtually unlimited for 
the development of desirable nanoparticles.
MAtErIAL ANd MEtHOds
synthesis of cy3-labeled carboxylated EstA
ESTA (5’-CGCTCGGA*TCGA*TA*A*GCTT
CGA*TCCCA*CTCTCCCGTTCA*CTTCTCCTCA
*C GTCA*CGGA*TCCTCTA*GA*GCA*CTG-3’, * 
indicates thioation) was chemically synthesized in a DNA 
synthesizer (Expedite 8909, Applied Biosystems) using 
the standard phosphoramidite chemistry as described 
previously [30]. The 5’ end of the ESTA was coupled with 
Cy3 phosphoramidite with the MMT protective group 
remaining and followed by the addition of 5’-carboxy 
modifier-C10 containing N-hydroxy succinimide 
ester protective group. After functionalization, ESTA 
was cleaved from the bead support and the protecting 
groups were removed with 0.4M methanolic NaOH at 
room temperature for 24-36 hr. The resultant ESTA was 
further purified and the concentration of the ESTA was 
determined by measuring the absorbance at 260 nm with a 
UV spectrophotometer. 
Preparation of EstA conjugated liposome 
(EstA-lip)
Amino-PEG liposomes were made with a lipid 
mixture (50 mM) consisting of DPPC, cholesterol, and 
DSPE-PEG (2000) Amine, in a 58.9: 40: 1.1 molar ratio, 
dissolved in ethanol and then hydrated with either; (1) 10 
mM phosphate buffered saline to prepare empty liposomes 
or (2) 1 mM FITC solution for in vitro studies. This was 
then sequentially extruded using a Lipex thermoline 
extruder to prepare liposomes of approximately 100 
nm. The FITC-liposomes were diafiltered through 500 
kDa molecular weight cut-off membranes to remove un-
encapsulated dye. Rhodamine tagged liposomes used 
for in vivo studies were extruded as above. DPPC: Chol: 
DSPE-PEG (2000) amine : Rhodamine-DHPE at 58.8: 
40: 1.1 : 0.1 molar ratio were used. Carboxylated Cy3-
labeled or unlabeled ESTA was conjugated to amino PEG 
liposomes by using carbodiimide chemistry with EDC 
and sulfo-NHS. Free ESTA was removed by dialysis. 
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characterization of EstA-lips
The size and zeta potential of the ESTA conjugated 
liposome were measured using a ZetaPals instrument 
(Brookhaven Instruments). 2µl of liposomes were added 
to 1.4 mL of 10mM phosphate buffer (pH 7.3) and the 
analysis was conducted at room temperature (23°C) in 
triplicates. To quantify the concentration of the ESTA 
on the liposomes, Cy3 fluorescence from ESTA-lip was 
measured and compared with ESTA standard curve. Fourier 
transform infrared spectroscopy (FTIR) was preformed to 
assess the attachment of ESTA on the liposomes. Samples 
were diluted in de-ionized water and FTIR was preformed 
on a Nicolet 6700 (Thermo Scientific, Waltham, MA). A 
2µL drop from each sample was placed on the diamond 
crystal and subjected to vacuum. Using a smart diamond 
crystal attenuated total reflection (ATR) accessory each 
sample was run for 150 scans at a resolution of 4 wave 
numbers.
Induction of E-selectin expression in HUVEc 
cells
To induce E-selectin expression, the cells were 
stimulated with TNF-α (10ng/ml) for 2 to 4 h. To 
determine E-selectin expression on the endothelial cell 
surface, the cells were dissociated with 5 mM EDTA and 
then incubated with FITC labeled E-selectin antibody 
(Pharmingen). As a negative control, the same amount 
of normal IgG was used. The surface fluorescence was 
measured by a FACS Caliber. The experiments were 
repeated at least three times and data represent an average 
value. 
EstA-lip binding to E-selectin expressing 
endothelial cells
100 nM of Cy3-ESTA conjugated liposomes 
encapsulating FITC (Cy3-ESTA-lip-FITC) were 
incubated with HUVEC that were treated or untreated 
with TNF-α for 2 hours at 37ºC. As a negative control, 
NH2 PEG liposomes encapsulating FITC (NH2-PEG-lip) 
were used. Following 3 hours incubation, the cells were 
briefly washed with tissue culture media to remove the 
unbound liposomes and then incubated overnight. The 
cells were fixed with 4% paraformaldehyde, and the nuclei 
were counterstained with 1.0 µg/ml Hoechst 33342. The 
fluorescent signals were detected using TE2000-E, Nikon 
fluorescent microscope (x600 magnification) to determine 
the binding to the cells. All images were acquired under 
the same exposure conditions for the comparison of 
liposome binding to the cells.
In vivo carcinoma mouse model
5-week old female athymic nu/nu nude mice 
(Charles River) were maintained in a VAF-barrier 
facility and all animal procedures were performed in 
accordance with the regulations in the Institutional 
Animal Care and Use Committee at the University of 
Texas Health Science Center at Houston. An orthotopic 
breast tumor was established as previously reported 
with minor modification. When tumors became palpable 
(approx. 200-300 mm3), either encapsulated ESTA-lip-
rhodamine or NH2-PEG-lip (3 mg of total lipid in 100 
µl of saline) was intravenously injected into mice via 
tail vein (n=3 per group). One day after the injection, the 
tumors were harvested and immediately mounted in OCT 
media for subsequent histological analysis. To examine 
tumor localization of liposomes, the frozen tissues were 
sectioned (8 µm thickness) and analyzed by fluorescent 
microscope. The frozen sections were also immunostained 
as previously reported [14]. 
Pharmacokinetics of liposomes
Following a single intravenous bolus administration 
of the ESTA-Lip-Rhodamine or NH2-PEG-Lip (3 mg 
of total lipid in 100 µl of saline) into 10 weeks old FBV 
mice (n=3-4), whole blood was collected at different time 
points by cardiac puncture. The fluorescence intensity 
in the plasma (50 µl) was measured using a fluorimeter 
at 544/594 nm (excitation/emission wavelengths) to 
determine the pharmacokinetics parameters of each 
liposome. Plasma samples were also collected from 
untreated mice as a baseline.
AcKNOWLEdGEMENts
We thank S. Amra for her help with the histological 
sections.
GrANt sUPPOrt 
This research was supported by grants from the 
Department of Defense W81XWH11-1-0238 (T.T), 
Alliance for Nanohealth USAMRMC10117004 (T.T, A.A, 
D.G), and National Institute of Health, AI 27744 (D.G.), 
GM 084552 (D.G.), HHSN272200800048C (D.G.), NCI 
U54CA151668 (D.G. and M.F.) and N01-HV-28184 
(D.G.), The Welch Foundation (H-1296) (D.G.) and 
Alliance for NanoHealth Training Program supported by 
NASA NNX08AW91G (A.M).
rEFErENcEs
1. Farokhzad OC, Langer R. Impact of nanotechnology on 
Oncotarget 2011; 2:  298 - 304304www.impactjournals.com/oncotarget
drug delivery. ACS Nano 2009, 3(1):16-20.
2. Ferrari M. Cancer nanotechnology: opportunities and 
challenges. Nat Rev Cancer 2005, 5(3):161-171.
3. Qiao Y, Huang X, Nimmagadda S, Bai R, Staedtke V, Foss 
CA, Cheong I, Holdhoff M, Kato Y, Pomper MG, Riggins 
GJ, Kinzler KW, Diaz LA Jr, Vogelstein B, Zhou S.A 
robust approach to enhance tumor-selective accumulation 
of nanoparticles. Oncotarget 2011, 2(1-2):59-68.
4. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston 
G, Roberge S, Jain RK, McDonald DM. Openings between 
defective endothelial cells explain tumor vessel leakiness. 
Am J Pathol 2000, 156(4):1363-1380.
5. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular 
architecture in a mammary carcinoma: branching patterns 
and vessel dimensions. Cancer Res 1991, 51(1):265-273.
6. Hortobagyi GN: Anthracyclines in the treatment of cancer. 
An overview. Drugs 1997, 54 Suppl 4:1-7.
7. Rivera E. Liposomal anthracyclines in metastatic breast 
cancer: clinical update. Oncologist 2003, 8 Suppl 2:3-9.
8. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev 
Cancer 2005, 5(6):436-446.
9. Burdick MM, McCarty OJ, Jadhav S, Konstantopoulos 
K. Cell-cell interactions in inflammation and cancer 
metastasis. IEEE Eng Med Biol Mag 2001, 20(3):86-91.
10. Siegel G, Malmsten M. The role of the endothelium in 
inflammation and tumor metastasis. Int J Microcirc Clin 
Exp 1997, 17(5):257-272.
11. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. 
Targeting selectins and selectin ligands in inflammation 
and cancer. Expert Opin Ther Targets 2007, 11(11):1473-
1491.
12. Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, 
DuBridge RB, Evangelista F, Henshall SM, Hevezi P, 
Miller JC, Pong M, Powers R, Senter P, Stockett D, 
Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray 
R, Afar DE, Ramakrishnan V. E-selectin up-regulation 
allows for targeted drug delivery in prostate cancer. Cancer 
Res 2003, 63(19):6387-6394.
13. Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U. 
Selectins--potential pharmacological targets? Drug Discov 
Today 2006, 11(21-22):1034-1040.
14. Mann AP, Somasunderam A, Nieves-Alicea R, Li X, 
Hu A, Sood AK, Ferrari M, Gorenstein DG, Tanaka T. 
Identification of thioaptamer ligand against E-selectin: 
potential application for inflamed vasculature targeting. 
PLoS One 2010, 5(9).
15. Tomczok J, Sliwa-Tomczok W, Klein CL, Bittinger F, 
Kirkpatrick CJ. Application of immunogold labelling for 
light and electron microscopic localization of endothelial 
leukocyte adhesion molecule 1 (ELAM-1) on cultured 
human endothelial cells. Micron 1994, 25(3):257-266.
16. Locardi E, Mullen DG, Mattern RH, Goodman M. 
Conformations and pharmacophores of cyclic RGD 
containing peptides which selectively bind integrin alpha(v)
beta3. J Pept Sci 1999, 5(11):491-506.
17. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins 
as receptors for tumor targeting by circulating ligands. Nat 
Biotechnol 1997, 15(6):542-546.
18. Pfaff M, Tangemann K, Muller B, Gurrath M, Muller G, 
Kessler H, Timpl R, Engel J. Selective recognition of cyclic 
RGD peptides of NMR defined conformation by alpha IIb 
beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol 
Chem 1994, 269(32):20233-20238.
19. Pan X, Lee RJ. Tumour-selective drug delivery via folate 
receptor-targeted liposomes. Expert Opin Drug Deliv 2004, 
1(1):7-17.
20. Sega EI, Low PS. Tumor detection using folate receptor-
targeted imaging agents. Cancer Metastasis Rev 2008, 
27(4):655-664.
21. Montet X, Funovics M, Montet-Abou K, Weissleder R, 
Josephson L. Multivalent effects of RGD peptides obtained 
by nanoparticle display. J Med Chem 2006, 49(20):6087-
6093.
22. Aragnol D, Leserman LD. Immune clearance of liposomes 
inhibited by an anti-Fc receptor antibody in vivo. Proc Natl 
Acad Sci U S A 1986, 83(8):2699-2703.
23. Harding JA, Engbers CM, Newman MS, Goldstein NI, 
Zalipsky S. Immunogenicity and pharmacokinetic attributes 
of poly(ethylene glycol)-grafted immunoliposomes. 
Biochim Biophys Acta 1997, 1327(2):181-192.
24. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. 
Nat Rev Drug Discov, 9(7):537-550.
25. Yang X, Gorenstein DG. Progress in thioaptamer 
development. Curr Drug Targets 2004, 5(8):705-715.
26. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and 
characterization of nuclease-stabilized RNA molecules that 
bind human prostate cancer cells via the prostate-specific 
membrane antigen. Cancer Res 2002, 62(14):4029-4033.
27. Teng Y, Girvan AC, Casson LK, Pierce WM, Jr., Qian M, 
Thomas SD, Bates PJ. AS1411 alters the localization of a 
complex containing protein arginine methyltransferase 5 
and nucleolin. Cancer Res 2007, 67(21):10491-10500.
28. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff 
PW, Richie JP, Langer R. Targeted nanoparticle-aptamer 
bioconjugates for cancer chemotherapy in vivo. Proc Natl 
Acad Sci U S A 2006, 103(16):6315-6320.
29. Feng L, Chen Y, Ren J, Qu X. A graphene functionalized 
electrochemical aptasensor for selective label-free detection 
of cancer cells. Biomaterials 2011.
30. Geiser T. Large-scale economic synthesis of antisense 
phosphorothioate analogues of DNA for preclinical 
investigations. Ann N Y Acad Sci 1990, 616:173-183.
